Current Report Filing (8-k)
06 Juni 2017 - 6:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 6, 2017
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(617) 431-2313
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
On June 6, 2017, Arch Therapeutics, Inc. (the “
Company
”)
issued a press release in connection with the corporate update that it presented at the LD Micro Invitational at the Luxe Sunset
Boulevard Hotel in Los Angeles, California. The text of the press release is attached hereto as
Exhibit 99.1
and is incorporated
by reference herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated
herein by reference.
|
Item 9.01
|
Financial Statements and Exhibit
|
(d) Exhibits
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on June 6, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
Dated: June 6, 2017
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name:
|
Terrence W. Norchi, M.D.
|
|
|
Title:
|
President, Chief Executive Officer
|
|
|
|
|
|
Exhibit
List
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued by Arch Therapeutics, Inc. on June 6, 2017
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Arch Therapeutics, Inc. News-Artikel